Fax: (011) 61-08-9346-4122
Optimizing the multimodal approach to pancreatic cyst fluid diagnosis †
Developing a volume-based triage protocol
Article first published online: 7 SEP 2012
Copyright © 2012 American Cancer Society
Volume 121, Issue 2, pages 86–100, February 2013
How to Cite
Chai, S. M., Herba, K., Kumarasinghe, M. P., de Boer, W. B., Amanuel, B., Grieu-Iacopetta, F., Lim, E. M., Segarajasingam, D., Yusoff, I., Choo, C. and Frost, F. (2013), Optimizing the multimodal approach to pancreatic cyst fluid diagnosis . Cancer Cytopathology, 121: 86–100. doi: 10.1002/cncy.21226
See editorial on pages 57–60, this issue.
- Issue published online: 5 FEB 2013
- Article first published online: 7 SEP 2012
- Manuscript Accepted: 18 JUN 2012
- Manuscript Revised: 10 JUN 2012
- Manuscript Received: 5 APR 2012
- pancreatic cyst;
- carcinoembryonic antigen;
- KRAS mutation;
- cytologic techniques;
- cyst fluid analysis;
- molecular analysis
The objective of this study was to develop a triage algorithm to optimize diagnostic yield from cytology, carcinoembryonic antigen (CEA), and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) testing on different components of a single pancreatic cyst fluid specimen. The authors also sought to determine whether cell block supernatant was suitable for CEA and KRAS testing.
Fifty-four pancreatic cysts were triaged according to a volume-dependent protocol to generate fluid (neat and supernatant) and cell block specimens for cytology, comparative CEA, and KRAS testing. Follow-up histology, diagnostic cytology, or a combined clinicopathologic interpretation was recorded as the final diagnosis.
There were 26 mucinous cystic lesions and 28 nonmucinous cystic lesions with volumes ranging from 0.3 mL to 55 mL. Testing different components of the specimens (cell block, neat, and/or supernatant) enabled all laboratory investigations to be performed on 50 of 54 cyst fluids (92.6%). Interpretive concordance was observed in 17 of 17 cases (100%) and in 35 of 40 cases (87.5%) that had multiple components tested for CEA and KRAS mutations, respectively. An elevated CEA level (>192 ng/mL) was the most sensitive test for the detection of a mucinous cystic lesion (62.5%) versus KRAS mutation (56%) and “positive” cytology (61.5%). KRAS mutations were identified in 2 of 25 mucinous cystic lesions (8%) in which cytology and CEA levels were not contributory.
A volume-based protocol using different components of the specimen was able to optimize diagnostic yield in pancreatic cyst fluids. KRAS mutation testing increased diagnostic yield when combined with cytology and CEA analysis. The current results demonstrated that supernatant is comparable to neat fluid and cell block material for CEA and KRAS testing. Cancer (Cancer Cytopathol) 2013. © 2012 American Cancer Society.